Re-evaluation of the relative potency of synthetic and natural α-tocopherol: Experimental and clinical observations

Journal of Nutritional Biochemistry

Volumn 15, Issue 7, 2004, Pages 380-395

  Blatt, David H ^a,b,d   Pryor, William A ^a   Mata, John E ^c   Rodriguez Proteau, Rosita ^c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Oregon Anesthesiology Group   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Tocopherol; Bioavailability; Drug interactions; Saturability; Stereospecificity; Tocopherol transfer protein

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; GAMMA TOCOPHEROL; KETOCONAZOLE; NICOTINIC ACID; RIFAMPICIN; SELENIUM; SESAMIN; SIMVASTATIN;

ALPHA TOCOPHEROL DEFICIENCY; ANTIOXIDANT ACTIVITY; CLINICAL OBSERVATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DIASTEREOISOMER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; HUMAN; MUSCULAR DYSTROPHY; NONHUMAN; NUTRITION; PREDICTION; REVIEW; STEREOSPECIFICITY;

ALPHA-TOCOPHEROL; ANIMALS; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERAPEUTIC EQUIVALENCY; VITAMIN E DEFICIENCY;

ANIMALIA;

EID: 3042517763     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2003.12.011     Document Type: Review

References (114)

1. Weiser H., Vecchi M. Stereoisomers of α-tocopheryl acetate characterization of the samples by physico-chemical methods and determination of biological activities in the rat resorption-gestation test. Int J Vitam Nutr Res. 51:1981;100-113
2. Traber M.G. Vitamin E. Shils M.E., Olson J.A., Shike M., Ross A.C. Modern Nutrition in Health and Disease. 1999;347-362 Williams and Wilkins, Baltimore
3. Machlin L.J. Vitamin E. Machlin L.J. Handbook of Vitamins. 1991;99-144 Marcel Dekker, New York
4. Shargel L., Yu A.B.C. Applied Biopharmaceutics and Pharmacokinetics. 1999;Appleton-Lange, Stamford, CT
5. Ravis W.R., Owen J.S. Stereochemical considerations in bioavailability studies. Jackson A.J. Generics and bioequivalence. 1994;CRC Press, Boca Raton
6. Mehvar R., Jamali F. Bioequivalence of chiral drugs. Stereospecific versus non stereospecific methods. Clin Pharmacokinet. 33:1997;122-141
7. Lane R.M., Baker G.B. Chirality and drugs used in psychiatry nice to know or need to know? Cell Mol Neurobiol. 19:1999;355-372
8. Nau C., Strichartz G.R. Drug chirality in anesthesia. Anesthesiology. 97:2002;497-502
9. Gristwood R.W. Cardiac and CNS toxicity of levobupivacaine strengths of evidence for advantage over bupivacaine. Drug Saf. 25:2002;153-163
10. Ekatodramis G., Borgeat A. The enantiomers revolution or evolution. Curr Top Med Chem. 1:2001;205-206
11. Mascagni P., Sabbatini V., Biordi L., Martinotti S., Allegretti M., Marullo A., Caselli G., Bertini R. R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production. Eur Cytokine Netw. 11:2000;185-192
12. Evans A.M. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 20:(suppl 1):2001;S9-S14
13. Mader R.M., Steger G.G., Rizovski B., Djavanmard M.P., Scheithauer W., Jakesz R., Rainer H. Stereospecific pharmacokinetics of rac-5- methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol. 40:1995;209-215
14. Zhu X., Ding Y., Lin B., Jakob A., Koppenhoefer B. Study of enantioselective interactions between chiral drugs and serum albumin by capillary electrophoresis. Electrophoresis. 20:1999;1869-1877
15. Weissinger J. Utility of kinetic, dynamic, and metabolic data in nonclinical pharmacology/toxicology studies. Yacobi A., Skelly J.P., Shah V.P., Benet L.Z. Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. 1993;Plenum Press, New York
16. 5th Supplement to the United States Pharmacopeia 19th edition and the National Formulary 14th edition. 1979;The United States Pharmacopeial Convention, Rockville, MD
17. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. 2000;National Academy Press, Washington, DC
18. Burton G.W., Ingold K.U., Traber M.G., Kayden H.J. Reply to W Cohn (. letter) Am J Clin Nutr. 69:1999;156-158
19. Devaraj S., Adams-Huet B., Fuller C.J., Jialal I. Dose-response comparison of RRR- and all-rac-α-tocopherol on LDL oxidation. Arterioscler Thromb Vasc Biol. 17:1997;2273-2279
20. Hosomi A., Arita M., Sato Y., Kiyose C., Ueda T., Igarashi O., Arai H., Inoue K. Affinity for α-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett. 409:1997;105-108
21. Burton G.W., Traber M.G., Acuff R.V., Walters D.N., Kayden H.J., Hughes L., Ingold K.U. Human plasma and tissue α-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr. 67:1998;669-684
22. Acuff R.V., Thedford S.S., Hidiroglou N.N., Papas A.M., Odom T.A. Jr. Relative bioavailability of RRR- and all-rac-α-tocopheryl acetate in humans studies using deuterated compounds. Am J Clin Nutr. 60:1994;397-402
23. Traber M.G., Winklhofer-Roob B.M., Roob J.M., Khoschsorur G., Aigner R., Cross C., Ramakrishnan R., Brigelius-Flohe R. Vitamin E kinetics in smokers and nonsmokers. Free Radic Biol Med. 31:2001;1368-1374
24. Traber M.G., Rader D., Acuff R., Brewer H.B., Kayden H.J. Discrimination between RRR- and all-rac-α-tocopherols labeled with deuterium by patients with abetalipoproteinemia. Atherosclerosis. 108:1994;27-37
25. Traber M.G. Vitamin E too much or not enough? Am J Clin Nutr. 73:2001;997-998
26. Fletcher R.H., Fairfield K.M. Vitamins for chronic disease prevention in adults clinical applications. JAMA. 287:2002;3127-3129
27. Willett W.C., Stampfer M.J. Clinical practice what vitamins should I be taking, doctor? N Engl J Med. 345:2001;1819-1824
28. Derendorf H., Lesko L.J., Chaikin P., Colburn W.A., Lee P., Miller R., Powell R., Rhodes G., Stanski D., Venitz J. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 40:2000;1399-1418
29. Hoppe P.P., Kraemer K. Bioavailability and biopotency of vitamin E in humans an ongoing controversy. Packer L., Traber M.G., Kraemer K., Frei B. The antioxidant vitamins C and E. 2003;152-160 AOCS Press, Champaign, IL
30. Traber M.G., Blatt D.H. Vitamin E evidence for the 2:1 preference for RRR- compared to all-rac-α-tocopherols. Packer L., Traber M.G., Kraemer K., Frei B. The antioxidant vitamins C and E. 2003;161-170 AOCS Press, Champaign, Illinois
31. Traber M.G., Rudel L.L., Burton G.W., Hughes L., Ingold K.U., Kayden H.J. Nascent VLDL from liver perfusions of cynomolgus monkeys are preferentially enriched in RRR- compared with SRR-α tocopherol studies using deuterated tocopherols. J Lipid Res. 31:1990;687-694
32. Weiser H., Riss G., Kormann A.W. Biodiscrimination of the eight α-tocopherol stereoisomers results in preferential accumulation of the four 2R forms in tissues and plasma of rats. J Nutr. 126:1996;2539-2549
33. Kiyose C., Muramatsu R., Kameyama Y., Ueda T., Igarashi O. Biodiscrimination of α-tocopherol stereoisomers in humans after oral administration. Am J Clin Nutr. 65:1997;785-789
34. Acuff R.V., Dunworth R.G., Webb L.W., Lane J.R. Transport of deuterium-labeled tocopherols during pregnancy. Am J Clin Nutr. 67:1998;459-464
35. Ingold K.U., Burton G.W., Foster D.O., Hughes L., Lindsay D.A., Webb A. Biokinetics of and discrimination between dietary RRR- and SRR-α- tocopherols in the male rat. Lipids. 22:1987;163-172
36. Behrens W.A., Madere R. Tissue discrimination between dietary RRR-α- and all-rac-α-tocopherols in rats. J Nutr. 121:1991;454-459
37. Lauridsen C., Engel H., Jensen S.K., Craig A.M., Traber M.G. Lactating sows and suckling piglets preferentially incorporate RRR- over all-rac-α-tocopherol into milk, plasma and tissues. J Nutr. 132:2002;1258-1264
38. Goti D., Hammer A., Galla H.J., Malle E., Sattler W. Uptake of lipoprotein-associated α-tocopherol by primary porcine brain capillary endothelial cells. J Neurochem. 74:2000;1374-1383
39. Copp R.P., Wisniewski T., Hentati F., Larnaout A., Ben Hamida M., Kayden H.J. Localization of α-tocopherol transfer protein in brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. Brain Res. 822:1999;80-87
40. Hosomi A., Goto K., Kondo H., Iwatsubo T., Yokota T., Ogawa M., Arita M., Aoki J., Arai H., Inoue K. Localization of α-tocopherol transfer protein in rat brain. Neurosci Lett. 256:1998;159-162
41. Jishage K., Arita M., Igarashi K., Iwata T., Watanabe M., Ogawa M., Ueda O., Kamada N., Inoue K., Arai H., Suzuki H. α-Tocopherol transfer protein is important for normal development of placental labyrinthine trophoblasts in mice. J Biol Chem. 273:2001;1669-1672
42. Kamal-Eldin A., Appelqvist L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids. 31:1996;671-701
43. Horwitt M.K. Relative biological values of d-α-tocopheryl acetate and all-rac-α-tocopheryl acetate in man. Am J Clin Nutr. 33:1980;1856-1860
44. Horwitt M.K. Vitamin E and lipid metabolism in man. Am J Clin Nutr. 8:1960;451-461
45. Hoppe P.P., Krennrich G. Bioavailability and potency of natural-source and all-racemic-alpha-tocopherol in the human a dispute. Eur J Nutr. 39:2000;183-193
46. Traber M.G., Rader D., Acuff R., Ramakrishnan R., Brewer H.B., Kayden H.J. Vitamin E dose-response studies in humans with use of deuterated RRR-α-tocopherol. Am J Clin Nutr. 68:1998;847-853
47. Roodenburg A.J., Leenen R., van het Hof K.H., Weststrate J.A., Tijburg L.B. Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans. Am J Clin Nutr. 71:2000;1187-1193
48. Dimitrov N.V., Meyer C., Gilliland D., Ruppenthal M., Chenoweth W., Malone W. Plasma tocopherol concentration in response to supplemental vitamin E. Am J Clin Nutr. 53:1991;723-729
49. Iuliano L., Micheletta F., Maranghi M., Frati G., Diczfalusy U., Violi F. Bioavailability of vitamin E as function of food intake in healthy subjects. Arterioscler Thromb Vasc Biol. 21:2001;E34-E37
50. Blatt D.H., Leonard S.W., Traber M.G. Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition. 17:2001;799-805
51. Schuelke M., Elsner A., Finckh B., Kohlschutter A., Hubner C., Brigelius-Flohe R. Urinary α-tocopherol metabolites in α-tocopherol transfer protein-deficient patients. J Lipid Res. 41:2000;1543-1551
52. Schultz M., Leist M., Petrzika M., Gassmann B., Brigelius-Flohe R. Novel urinary metabolite of alpha-tocopherol, 2, 5, 7, 8-tetramethyl-2(2′- carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? Am J Clin Nutr. 62:(suppl):1995;1527S-1534S
53. Stahl W., Graf P., Brigelius-Flohe R., Wechter W., Sies H. Quantification of the α- and γ-tocopherol metabolites 2, 5, 7, 8-tetramethyl-2-(2′-carboxyethyl)-6-hydroxychroman and 2, 7, 8-trimethyl-2-(2′-carboxyethyl)-6-hydroxychroman in human serum. Anal Biochem. 275:1999;254-259
54. Verdon C.P., Blumberg J.B. Influence of dietary vitamin E on intermembrane transfer of α-tocopherol as mediated by an α-tocopherol binding protein. Proc Soc Exp Biol Med. 189:1988;52-60
55. Swanson J.E., Ben R.N., Burton G.W., Parker R.S. Urinary excretion of 2, 7, 8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman is a major route of elimination of γ-tocopherol in humans. J Lipid Research. 40:1999;665-671
56. Lodge J.K., Ridlington J., Leonard S., Vaule H., Traber M.G. α- and γ-Tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine. Lipids. 36:2001;43-48
57. Birringer M., Pfluger P., Kluth D., Landes N., Brigelius-Flohe R. Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells. J Nutr. 132:2002;3113-3118
58. Parker R.S., Sontag T.J., Swanson J.E. Cytochrome P4503A-dependent metabolism of tocopherols and inhibition by sesamin. Biochem Biophys Res Commun. 277:2000;531-534
59. Sontag T.J., Parker R.S. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism novel mechanism of regulation of vitamin E status. J Biol Chem. 277:2002;25290-25296
60. Birringer M., Drogan D., Brigelius-Flohe R. Tocopherols are metabolized in HepG2 cells by side chain ω-oxidation and consecutive β-oxidation. Free Radic Biol Med. 31:2001;226-232
61. Traber M.G., Elsner A., Brigelius-Flohe R. Synthetic as compared with natural vitamin E is preferentially excreted as α-CEHC in human urine studies using deuterated α-tocopheryl acetates. FEBS Lett. 437:1998;145-148
62. Mustacich D.J., Shields J., Horton R.A., Brown M.K., Reed D.J. Biliary secretion of α-tocopherol and the role of the mdr2 P-glycoprotein in rats and mice. Arch Biochem Biophys. 350:1998;183-192
63. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P4503A4 inhibition. Clin Pharmacokinet. 38:2000;41-57
64. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci. 12:2000;3-12
65. Oram JF, Vaughan AM, Stocker R. ABCA1 mediates cellular secretion of α-tocopherol. J Biol Chem 2001:276:39898-902
66. Cohn W. Evaluation of vitamin E potency. Am J Clin Nutr. 69:1999;156-158. Letter to the editor
67. Weiser H., Vecchi M. Stereoisomers of α-tocopheryl acetate biopotencies of all eight stereoisomers, individually or in mixtures, as determined by rat resorption-gestation tests. Int J Vitam Nutr Res. 52:1982;351-370
68. Handelman G.J., Machlin L.J., Fitch K., Weiter J.J., Dratz E.A. Oral α-tocopherol supplements decrease plasma γ-tocopherol levels in humans. J Nutr. 115:1985;807-813
69. Clement M., Bourre J.M. Graded dietary levels of RRR-γ-tocopherol induce a marked increase in the concentrations of α- and γ-tocopherol in nervous tissues, heart, liver and muscle of vitamin-E-deficient rats. Biochim Biophys Acta. 1334:1997;173-181
70. Saldeen T., Li D., Mehta J.L. Differential effects of α- and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 34:1999;1208-1215
71. Yamashita K., Iizuka Y., Imai T., Namiki M. Sesame seed and its lignans produce marked enhancement of vitamin E activity in rats fed a low α-tocopherol diet. Lipids. 30:1995;1019-1028
72. Yamashita K., Nohara Y., Katayama K., Namiki M. Sesame seed lignans and γ-tocopherol act synergistically to produce vitamin E activity in rats. J Nutr. 122:1992;2440-2446
73. Kamal-Eldin A., Petterson D., Appelqvist L.A. Sesamin (a compound from sesame oil) increases tocopherol levels in rats fed ad libitum. Lipids. 30:1995;499-505
74. Bittner B., Guenzi A., Fullhardt G., Gonzalez R.C., Mountfield R.J. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung. 52:2002;684-688
75. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 16:1999;1550-1556
76. Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos. 28:2000;522-528
77. Parker R.S., Swanson J.E. A novel 5′-carboxychroman metabolite of gamma-tocopherol secreted by HepG2 cells and excreted in human urine. Biochem Biophys Res Commun. 269:2000;580-583
78. Zhang J., Kuehl P., Green E.D., Touchman J.W., Watkins P.B., Daly A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Wrighton S.A., Hancock M., Kim R.B., Strom S., Thummel K., Russell C.G., Hudson J.R. Jr., Schuetz E.G., Boguski M.S. The human pregnane X receptor genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 11:2001;555-572
79. Dresser G.K., Schwarz U.I., Wilkinson G.R., Kim R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 73:2003;41-50
80. Brigelius-Flohe R. Vitamin E and drug metabolism. Biochem Biophys Res Commun. 305:2003;737-740
81. Ziemann C., Burkle A., Kahl G.F., Hirsch-Ernst K.I. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis. 20:1999;407-414
82. Felix R.A., Barrand M.A. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem. 80:2002;64-72
83. Wang E., Casciano C.N., Clement R.P., Johnson W.W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 18:2001;800-806
84. Brown B.G., Zhao X., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frochlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Eng J Med. 345:2001;1583-1592
85. Horwitt M.K., Century B., Zeman A.A. Erythrocyte survival time and reticulocyte levels after tocopherol depletion in man. Am J Clin Nutr. 12:1963;99
86. Roxborough H.E. BG, Kelly F.J. Inter- and intra-individual variation in plasma and red blood cell vitamin E after supplementation. Free Radic Res. 33:2000;437-445
87. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786
88. Traber M.G., Arai H. Molecular mechanisms of vitamin E transport. Annu Rev Nutr. 19:1999;343-355
89. Azzi A., Breyer I., Feher M., Pastori M., Ricciarelli R., Spycher S., Staffieri M., Stocker A., Zimmer S., Zingg J.M. Specific cellular responses to α-tocopherol. J Nutr. 130:2000;1649-1652
90. Upston J.M., Terentis A.C., Stocker R. Tocopherol-mediated peroxidation of lipoproteins implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 13:1999;977-994
91. Joffe M., Harris P.L. The biological potency of the natural tocopherols and certain derivatives. J Amer Chem Soc. 65:1943;925-928
92. Weiser H., Vecchi M., Schlachter M. Stereoisomers of α-tocopheryl acetate simultaneous determination of resorption-gestation and myopathy in rats in evaluating biopotency ratios of all-rac- and RRR-α-tocopheryl acetate. Int J Vitam Nutr Res. 55:1985;149-158
93. Hume E.M. Standardization of vitamin E. Nature. 148:1941;472-473
94. Harris P.L., Ludwig M.I. Relative vitamin E potency of natural and synthetic α-tocopherol. J Biol Chem. 179:1949;1111-1115
95. Mason K.E., Harris P.L. Bioassay of vitamin E. Biol Symp. 12:1947;459-483
96. Harris P.L., Ludwig M.I. Vitamin E potency of α-tocopherol and α-tocopherol esters. J Biol Chem. 180:1949;611-614
97. Ames S.R., Ludwig D.I., Nelan D.R., Robeson C.D. Biological activity of an l-epimer of d-α-tocopheryl acetate. Biochem. 2:1963;188
98. Ames S.R. Biopotency in rats of several forms of α-tocopherol. J Nutr. 109:1979;2198-2204
99. Leth T., Sondergaard H. Biological activity of vitamin E compounds and natural materials by the resorption-gestation test. J Nutr. 107:1977;2236-2243
100. Harris P.L., Jensen J.L., Joffe M., Mason K.E. Biological activity of natural and synthetic tocopherols. J Biol Chem. 156:1944;491-498
101. Leth T., Sondergaard H. Biological activity of all-rac-α-tocopherol and RRR-α-tocopherol determined by three different rat bioassays. Int J Vitam Nutr Res. 53:1983;297-311
102. Scott M.L., Desai I.D. The relative anti-muscular dystrophy activity of the d- and l-epimers of α-tocopherol and other tocopherols in the chick. J Nutr. 83:1964;39-43
103. Scott M.L. Comparative biological effectiveness of d-, dl-, and l-forms of α-tocopherol for prevention of muscular dystrophy in chicks. Fed Proc. 24:1965;901-905
104. Weiser H., Vecchi M., Schlachter M. Stereoisomers of α-tocopheryl acetate USP units and α-tocopherol equivalents of all-rac-, 2-ambo- and RRR-α-tocopherol evaluated by simultaneous determination of resorption-gestation, myopathy and liver storage capacity in rats. Int J Vitam Nutr Res. 56:1986;45-56
105. Sanathanan L.P., Peck C.C. Concentration-controlled trials basic concepts, design, and implementation. Yacobi A., Skelly J.P., Shah V.P., Benet L.Z. Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. 1993;Plenum Press, New York
106. Peck C.C. Rationale for the effective use of pharmacokinetics and pharmacodynamics in early drug development. Yacobi A., Skelly J.P., Shah V.P., Benet L.Z. Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. 1993;Plenum Press, New York
107. Wilkinson G.R. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 27:1997;129-159
108. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Cytochrome P450 3A ontogeny and drug disposition. Clin Pharmacokinet. 37:1999;485-505
109. Sadeque A.J., Wandel C., He H., Shah S., Wood A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 68:2000;231-237
110. Schinkel A.H. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther. 36:1998;9-13
111. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 100:1997;2430-2436
112. Sun H., Dai H., Shaik N., Elmquist W.F. Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 55:2003;83-105
113. Ushigome F., Koyabu N., Satoh S., Tsukimori K., Nakano H., Nakamura T., Uchiumi T., Kuwano M., Ohtani H., Sawada Y. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm Res. 20:2003;38-44
114. Nakamura Y., Ikeda S., Furukawa T., Sumizawa T., Tani A., Akiyama S., Nagata Y. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun. 235:1997;849-853